01 New IVIG Products Are Broadening Treatment Choice The Intravenous Immunoglobulin Market is seeing continued product development and regulatory approvals, giving healthcare systems more options for replacement therapy. IVIG is produced from donated human plasma and provides concentrated immunoglobulin G antibodies. New approvals matter because manufacturing is technically demanding and the market depends on a limited number of plasma fractionation networks. Additional products can diversify supply while increasing competition around purity, concentration, manufacturing consistency, packaging, and clinical evidence. Regulatory activity also shows that primary immunodeficiency remains an important commercial application. As more suppliers obtain approvals in major markets, hospitals and immunology centers gain additional treatment options while manufacturers expand their geographic reach and production requirements. In September 2025, the U.S. FDA approved Kedrion's QIVIGY, a 10% intravenous human immunoglobulin solution for treating adults with primary humoral immunodeficiency.
01 Expanding Use in Immune and Neurological Disorders Supports Demand IVIG demand is supported by its use across several immune and neurological conditions. Products such as PRIVIGEN are indicated for primary humoral immunodeficiency, chronic immune thrombocytopenic purpura, and chronic inflammatory demyelinating polyneuropathy in specified patient groups. This creates recurring demand because some patients require continuing replacement or immunomodulatory therapy rather than a single treatment. The commercial effect extends beyond immunology into neurology and hematology, allowing manufacturers to serve several specialist-care settings through the same plasma-derived product platform. Continued regulatory activity around established IVIG products also requires manufacturers to maintain clinical evidence, pharmacovigilance, production capacity, and dependable distribution as treatment populations and approved uses evolve.
01 Dependence on Donated Plasma Restricts Supply Flexibility Limited plasma availability is a structural restraint because immunoglobulin production cannot be expanded as quickly as conventional pharmaceutical manufacturing. Plasma must be collected from eligible donors, tested, pooled, fractionated, purified, and processed under strict quality requirements. WHO reports that only 49 of 168 reporting countries manufacture plasma-derived medicinal products using plasma collected domestically, while 119 reported relying completely on imports or not using these products during the reporting period. This concentration increases dependence on international collection and manufacturing networks. When demand rises faster than plasma collection or fractionation capacity, hospitals can face supply pressure, making plasma availability a fundamental constraint on IVIG market expansion.
01 Geographic Expansion Can Improve Access to Established IVIG Therapies Geographic expansion provides an important opportunity because access to plasma-derived medicines remains uneven between countries. Manufacturers with established IVIG products can grow by obtaining additional national registrations, strengthening distribution networks, and supporting healthcare systems where immunoglobulin availability is limited. This approach can be especially valuable because developing a completely new plasma-derived medicine requires considerable clinical and manufacturing investment, while extending an established product into additional countries can broaden access using an existing production platform. WHO also encourages countries to develop sustainable blood and plasma programs to improve equitable access to immunoglobulins and other plasma-derived medicines, creating opportunities across collection, fractionation, distribution, and finished-product supply.
01 Safety Surveillance and Batch Consistency Remain Critical Maintaining consistent safety across plasma-derived immunoglobulin lots is a major market challenge. IVIG is produced from biological starting material collected from many donors, so manufacturers need rigorous donor screening, purification, manufacturing controls, batch testing, traceability, and post-market surveillance. Even after regulatory approval, safety signals can require investigation, communication with healthcare professionals, or withdrawal of affected lots. These responsibilities increase quality-control costs and make manufacturing consistency central to brand reputation and supply continuity. The challenge is especially important because patients receiving immunoglobulin may require repeated treatment. Manufacturers therefore need to combine expanding production with strict pharmacovigilance and rapid investigation of unusual adverse-event patterns.
September 2025 Octapharma expanded its immunoglobulin therapy portfolio by introducing advancements in plasma-derived treatment solutions and strengthening production capabilities to support global demand for IVIG products.
July 2025 CSL expanded its immunoglobulin product portfolio by advancing manufacturing and supply chain initiatives for plasma-derived therapies, strengthening availability of IVIG treatments for immunodeficiency and neurological conditions.
June 2025 Grifols expanded its plasma-derived medicines business by increasing investments in plasma collection and fractionation capabilities, supporting production capacity for immunoglobulin therapies including IVIG.
May 2025 Takeda expanded its immunoglobulin therapy portfolio by strengthening manufacturing and supply capabilities for plasma-derived therapies, including intravenous immunoglobulin (IVIG), to support patients with immune deficiencies and autoimmune disorders.